Tags:Platform
CODA Biotherapeutics’ revolutionary chemogenetic platform aims to control the activity of cells to treat disease. With chemogenetics, the goal is to modify a target cell population using gene therapy to express a tunable “switch” protein. Cells modified with the “switch” can be activated or inactivated in a dose-dependent manner by a subsequently administered small molecule therapeutic, an effect that should only occur in the modified cells. CODA’s engineered receptors will be able to modulate the activity of virtually any cell in which the receptor is ectopically expressed, making them suitable for the treatment of many disorders. CODA can further tailor the therapy to a particular disease by simply changing the viral capsid, DNA regulatory elements, and route of administration.
Location: United States, California, South San Francisco
Member count: 11-50
Total raised: $47M
Founded date: 2014

Investors 1

Funding Rounds 2

DateSeriesAmountInvestorsDeal News
06.12.2021-$28M-finsmes.co...
17.09.2018Series A$19M-finsmes.co...

Mentions in press and media 14

DateTitleDescriptionCategoryAuthorSource
06.12.2021Coda Bioth...Coda Biotherapeutics, a San Fr...USA-finsmes.co...
03.12.2021Thank youThis is the web version of Ter...--fortune.co...
03.12.2021Thank youThis is the web version of Ter...--fortune.co...
02.12.2021CODA Bioth...SOUTH SAN FRANCISCO, Calif., D...--marketscre...
10.11.2020CODA Bioth... SOUTH SAN FRANCISCO, Calif.,...--prnewswire...
05.11.2019CODA Bioth...---mpmcapital...
05.11.2019Coda Bioth...If the researchers, executives...Coda Bioth...Jonathan S...techcrunch...
17.09.2018Coda Bioth...Coda Biotherapeutics, Inc., a ...USA-finsmes.co...
14.09.2018Term Sheet...BORING IS THE NEW BLACK Good ...--fortune.co...
13.09.2018 Versan...San Diego-based biotech invest...--socaltech....
Show more